Vulvovaginal candidiasis therapy in reproductive age women




vulvovaginal candidiasis, Candida albicans, fluconazole, clotrimazole, complex therapy


Objective of the study: was to determine the effectiveness of complex therapy with Fusys® (fluconazole, 150 mg tablets) in combination with Clofan® (clotrimazole, vaginal suppositories 500 mg) in the treatment of acute vulvovaginal candidiasis (VVC).

Materials and methods. 38 patients in the age of 22 to 42 were examined for acute VVC. C. albicans fungi were causative agent of VVC in all women. After vaginal candidiasis diagnosis was confirmed, all patients were prescribed oral systemic fluconazole 150 mg (Fusys®) once in combination with a single vaginal administration of Clofan® (clotrimazole, vaginal suppositories 500 mg) for acute VVC treatment. At the same time, they warned of the need to treat a partner (Fusys® gel was prescribed). Effectiveness of treatment was evaluated after 3; 7 and 30 days after therapy. Results. All study participants noted a decrease in the severity of itching and intensity of discharge from the genital tract on the third day after therapy. Clinical symptoms of VVC completely disappeared in 35 (92.1%) women by the end of the seventh day after treatment. Microscopic and cultural examination revealed no Candida fungi in 31 (81.6%) patients. The rest of the women who had candidiasis again were treated by once prescribed oral Fusys® (150 mg) in combination with a single vaginal administration of Clofan® suppositories (500 mg). Repeated microscopic and culture studies carried out after 7 days showed no fungi in these patients.

Conclusion. The effectiveness of VVC complex therapy in the study was 92.1%. The results indicate high clinical and microbiological efficacy of complex therapy in combination with fluconazole (Fusys®) and clotrimazole Clofan® for the VVC treatment in women of reproductive age

Author Biographies

Т. Г. Романенко, P.L. Shupik NMAPE of the MoH of Ukraine, Kyiv

MD, professor, Department of Obstetrics and Gynecology No. 1

О. М. Суліменко, P.L. Shupik NMAPE of the MoH of Ukraine, Kyiv

Postgraduate student of the Department of Obstetrics and Gynecology No. 1


  1. Paladine, H.L., Desai, U.A. “Vaginitis: diagnosis and treatment.” Am Fam Physician 97.5 (2018): 321–9.
  2. Rogovskaya, S.I. “On the question of optimizing the treatment of vulvovaginal candidiasis.” Gynecology. Endocrinology 1.89 (2014): 25–32.
  3. Sobel, J.D. “Recurrent vulvovaginal candidiasis.” Am J Obstet Gynecol 214 (2016): 15–21. DOI: 10.1016/j.ajog.2015.06.067
  4. Gonçalves, B., Ferreira, C., Alves, C.T., et al. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. 2016;42(6):905–927. DOI: 10.3109/1040841X.2015.1091805
  5. Turner, S.A., Butler, G. “The candida pathogenic species complex.” Cold Spring Harb Perspect Med 4.9 (2014): a019778. DOI: 10.1101/cshperspect. a019778
  6. Serov, V.N., Sukhikh, G.T., Prilepskaya, V.N., Radzinsky, V.E., eds. Guidelines for outpatient care in obstetrics and gynecology. Moscow. GEOTAR-Media (2016): 1136 p.
  7. Prilepskaya, V.N., Bayramova G.R. Vulvovaginal candidiasis. Clinical picture, diagnostics, principles of therapy. Moscow. GEOTAR-Media (2010): 80 p.
  8. Sherrard, J., Wilson, J., Donders, G., et al. “European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge (2018).” Int J STD AIDS 29.13 (2018): 1258–72. DOI: 10.1177/0956462418785451
  9. Swidsinski, A., Guschin, A., Tang, Q., et al. “Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms.” Am J Obstet Gynecol 220.1 (2019): 91.e1–91.e8. DOI: 10.10.
  10. Turner, S.A., Butler, G. “The candida pathogenic species complex.” Cold Spring Harb Perspect Med 4.9 (2014): a019778. DOI: 10.1101/ cshperspect. a019778
  11. Palmeira-de-Oliveira, R., Palmeira-de-Oliveira, A., Martinez-de-Oliveira, J. “New strategies for local treatment of vaginal infections.” Advanced Drug Delivery Reviews 92 (2015): 105–22. DOI: 10.1016/j.addr.2015.06.008
  12. Sardi, J.C.O., Scorzoni, L., Bernardi, T., et al. “Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.” J Med Microbiol 62.1 (2013): 10–24. DOI: 10.1099/jmm.0.045054-0
  13. Deorukhkar, S.C., Saini, S., Mathew, S. “Non-albicans Candida Infection: An Emerging Threat.” Interdiscip Perspect Infect Dis 2014 (2014): 615958. DOI: 10.1155/2014/615958
  14. Nobile, C.J., Johnson, A.D. “Candida albicans biofilms and human disease.” Annu Rev Microbiol 69 (2015): 71–92. DOI: 10.1146/annurev-micro-091014-104330
  15. Ramage, G., Rajendran, R., Sherry, L., Williams, C. “Fungal biofilm resistance.” Int J Microbiol 2012 (2012): 528521. DOI: 10.1155/2012/528521
  16. Sherry, L., Kean, R., McKloud, E., et al. “Biofilms formed by isolates from recurrent vulvovaginal candidiasis patients are heterogeneous and insensitive to fluconazole.” Antimicrob Agents Chemother 61.9 (2017): e01065–17. DOI: 10.1128/AAC.01065-17
  17. Blostein, F., Levin-Sparenberg, E., Wagner, J., Foxman, B. “Recurrent vulvovaginal candidiasis.” Annals of Epidemiology 27.9 (2017): 575–82. DOI: 10.1016/j. annepidem.2017.08.010
  18. Mgeryan, A.N. “Vulvovaginal candidiasis: the effectiveness of clotrimazole therapy.” Effective pharmacotherapy 15.26 (2019): 36–41. DOI: 10.33978/2307-3586-2019-15-26-36-41
  19. Roberts, C., Algert, C., Morris, J., Rickard, K. “Treating vaginal candidiasis for the prevention of preterm birth: protocol for a systematic review and metaanalysis.” Systematic Review 4 (2015): 31. DOI: 10.1186/s13643-015-0018-2
  20. Workowski, K.A., Bolan, G.A. “Sexually transmitted diseases treatment guidelines, 2015.” The MMWR Recommendations and Reports 64.RR3 (2015): 1–137.



How to Cite

Романенко, Т. Г., & Суліменко, О. М. (2020). Vulvovaginal candidiasis therapy in reproductive age women. REPRODUCTIVE ENDOCRINOLOGY, (54), 86–88.